Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021, with a specific reporting date of February 19, 2021. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the UK Market Abuse Regulation. The filing details the vesting of conditional share awards granted in 2018 under the GSK Share Value Plan and the subsequent sale of shares to meet associated tax liabilities.
Key Financial Metrics
The filing does not contain corporate financial statements, revenue, profit, cash flow, or debt metrics. It reports specific transaction data for individual executives:
- Transaction Type: Vesting of Ordinary Shares and sale of Ordinary Shares to meet tax liabilities.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: Vesting occurred at £0.00. Sales to meet tax liabilities occurred at £12.6818 per share.
- Transaction Dates: February 15, 2021, and February 17, 2021.
- Exchange: London Stock Exchange (XLON) for sales; N/A for vesting.
Material Changes
The filing does not report material changes to the company's business operations, financial position, or market conditions. It strictly documents routine equity compensation events for the following individuals:
- Ms. D. Conrad: SVP, Human Resources (Vested 10,050 shares; received cash equivalent of £127,452.09 less tax).
- Ms. S. Jackson: SVP, Global Communications & CEO Office (Vested 11,060 shares; sold 5,199 shares).
- Mr. D. Jackson: PCA of Ms. S. Jackson (Vested 6,330 shares; sold 2,976 shares).
- Ms. D. Waterhouse: CEO of ViiV Healthcare (Vested 15,160 shares; sold 7,126 shares).
- Ms. V. Whyte: Company Secretary (Vested 11,060 shares; sold 5,199 shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The document is a statutory disclosure of specific share transactions and does not address the company's strategic direction or future performance.
Investor Verification Checklist
- Verify the total number of shares sold by PDMRs to meet tax liabilities against the company's overall share buyback or treasury stock policies.
- Confirm the market price of GSK shares on February 15 and 17, 2021, to validate the reported transaction price of £12.6818.
- Review the 2018 Share Value Plan terms to understand the vesting conditions that triggered these awards.
- Check subsequent filings to ensure all tax withholding obligations related to these vesting events were settled.